Market Price

82.96 

-1.54 -1.8%

as of Feb 03 '23

52 Week Range:

0.34 85.16


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 2.26
3.52
3.42
3.20
2.88
2.95
2.53
2.27
1.85
0.94
0.43
growth rate 55.8% -2.8% -6.4% -10.0% 2.4% -14.2% -10.3% -18.5% -49.2% -54.3%
Earnings BIT -31.57
-35.43
-60.49
-116.28
-137.85
-139.00
-141.54
-142.80
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -4.85
-16.76
-16.76
-16.76
-16.76
-16.76
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROA 21.83
24.03
-12.36
-9.24
-11.15
-16.12
-19.92
-27.33
-34.44
-69.91
-102.89
growth rate 10.1% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE 37.02
40.02
-21.95
-17.06
-21.74
-30.53
-31.07
-37.82
-47.58
-99.11
-174.51
growth rate 8.1% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC 36.97
34.52
-16.57
-11.09
-13.64
-18.35
-25.76
-37.74
-48.72
-98.95
-171.97
growth rate -6.6% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 2.88
2.06
2.61
2.03
2.51
3.30
2.53
2.90
3.94
3.51
1.95
growth rate -28.5% 26.7% -22.2% 23.7% 31.5% -23.3% 14.6% 35.9% -10.9% -44.4%
Quick Ratio 2.71
1.83
2.41
1.91
2.41
3.11
2.39
2.75
3.77
3.43
1.91
growth rate -32.5% 31.7% -20.8% 26.2% 29.1% -23.2% 15.1% 37.1% -9.0% -44.3%
Leverage 1.50
1.78
1.77
1.92
1.98
1.82
1.39
1.38
1.38
1.46
2.35
growth rate 18.7% -0.6% 8.5% 3.1% -8.1% -23.6% -0.7% 0.0% 5.8% 61.0%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 76.25
42.96
45.54
34.39
33.57
10.00
2.46
1.03
growth rate -43.7% 6.0% -24.5% -2.4% -70.2% -75.4% -58.2%
Acct.Payable 24.57
26.68
30.49
33.65
44.92
32.01
34.39
33.41
growth rate 8.6% 14.3% 10.4% 33.5% -28.7% 7.4% -2.8%
Cur.Assets 222.47
190.63
216.65
277.75
250.69
244.02
186.65
103.95
growth rate -14.3% 13.7% 28.2% -9.7% -2.7% -23.5% -44.3%
Total Assets 490.03
419.05
428.77
487.44
390.89
263.43
196.80
111.55
growth rate -14.5% 2.3% 13.7% -19.8% -32.6% -25.3% -43.3%
Cash 129.94
139.74
158.22
227.32
157.48
64.42
46.01
88.54
growth rate 7.5% 13.2% 43.7% -30.7% -59.1% -28.6% 92.4%
Inventory 9.20
4.18
8.72
5.72
3.55
growth rate -54.6% 108.7% -34.4% -37.9%
Cur.Liabilities 109.44
76.34
65.51
109.75
98.33
61.97
53.15
53.23
growth rate -30.2% -14.2% 67.5% -10.4% -37.0% -14.2% 0.2%
Liabilities 235.48
206.19
192.74
136.10
119.48
73.04
62.56
64.00
growth rate -12.4% -6.5% -29.4% -12.2% -38.9% -14.4% 2.3%
LT Debt 96.30
99.38
97.04
growth rate 3.2% -2.4%
Equity 254.43
212.73
236.03
351.34
271.41
190.39
134.24
47.55
growth rate -16.4% 11.0% 48.9% -22.8% -29.9% -29.5% -64.6%
Common Shares 58.00
65.00
61.00
65.00
65.00
73.00
85.00
0.11
0.11
0.15
0.17
growth rate 12.1% -6.2% 6.6% 0.0% 12.3% 16.4% -99.9% 2.7% 29.2% 13.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 0.93
0.22
0.08
0.47
0.11
9.02
5.54
0.22
growth rate -76.1% -65.0% 496.2% -77.0% 8,328.0% -38.6% -96.0%
Cash Dividends 0.01
0.01
0.01
growth rate 0.0% 0.0%
Cash From OA -3.63
6.74
-40.46
-38.86
-62.40
-134.63
-121.63
-119.49
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share 0.58
0.88
-0.06
-0.10
0.20
-0.47
-0.31
-0.54
-1.04
-0.89
-0.70
growth rate 51.7% -100.0% 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 2.55
2.11
74.74
134.76
growth rate -17.1% 3,443.9% 80.3%
FCF 43.00
46.00
-5.00
-5.00
7.00
-41.00
-39.00
-65.00
-144.00
-127.00
-120.00
growth rate 7.0% -100.0% 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 186.83
162.56
146.44
128.37
109.33
growth rate -13.0% -9.9% -12.3% -14.8%
Op.Income -31.57
-35.43
-60.49
-116.28
-137.85
-139.00
-141.54
-142.80
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -43.53
-52.24
-72.08
-122.69
-128.61
-144.59
-171.33
-158.43
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -45.72
-52.64
-69.77
-92.19
-120.74
-112.69
-160.87
-158.63
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS 0.86
1.46
-1.02
-0.71
-0.81
-0.96
-1.08
-1.17
-1.02
-1.29
-1.02
growth rate 69.8% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 159.79
134.87
110.60
81.15
82.58
growth rate -15.6% -18.0% -26.6% 1.8%
R&D 69.66
51.07
59.12
51.53
75.16
79.13
81.18
87.30
growth rate -26.7% 15.8% -12.9% 45.9% 5.3% 2.6% 7.5%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT -44.07
-33.09
-31.95
-14.06
-25.39
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 3.53
3.86
1.03
0.64
0.61
growth rate 9.4% -73.4% -37.8% -4.9%
Acct.Payable 41.86
40.91
33.41
25.31
26.15
growth rate -2.3% -18.4% -24.3% 3.4%
Cur.Assets 165.71
140.00
103.95
93.18
73.58
growth rate -15.5% -25.8% -10.4% -21.0%
Total Assets 175.05
147.80
111.55
100.05
79.43
growth rate -15.6% -24.5% -10.3% -20.6%
Cash 114.57
107.44
88.54
78.68
25.51
growth rate -6.2% -17.6% -11.1% -67.6%
Inventory
growth rate
Cur.Liabilities 56.70
57.27
53.23
39.21
41.04
growth rate 1.0% -7.1% -26.3% 4.7%
Liabilities 66.46
68.34
64.00
44.80
45.99
growth rate 2.8% -6.4% -30.0% 2.7%
LT Debt
growth rate
Equity 108.59
79.46
47.55
55.26
33.44
growth rate -26.8% -40.2% 16.2% -39.5%
Common Shares 0.16
0.16
0.17
0.18
0.19
growth rate 0.0% 0.6% 8.5% 3.4%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 0.07
0.08
0.08
0.04
0.01
growth rate 20.9% 0.0% -51.9% -84.6%
Cash From OA -29.65
-25.00
-30.35
-30.30
-23.45
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -29.72
-25.08
-30.43
-30.34
-23.45
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales
growth rate
Op.Income -44.07
-33.09
-31.95
-14.06
-25.39
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -49.92
-33.07
-39.76
-15.39
-29.03
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -50.13
-33.08
-39.72
-15.44
-29.05
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit
growth rate
R&D 29.11
20.85
17.96
4.19
16.01
growth rate -28.4% -13.9% -76.7% 281.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -16.76 -77.10 -0.48
EPS / Growth 63.0% -1.08

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 32.0% 32.0%
Future PE 0.01 0.01 21.35
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.